The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome. Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity. T...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Haematologica
Glavni autori: Kraus, Marianne, Bader, Juergen, Geurink, Paul P., Weyburne, Emily S., Mirabella, Anne C., Silzle, Tobias, Shabaneh, Tamer B., van der Linden, Wouter A., de Bruin, Gerjan, Haile, Sarah R., van Rooden, Eva, Appenzeller, Christina, Li, Nan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2015
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591768/
https://ncbi.nlm.nih.gov/pubmed/26069288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.109421
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items